Renal Clear Cell Non-Clear Cell

Localized

T1b or greater (has not spread beyond the kidney)

Metastatic/locally advanced

Clear Cell

No Prior Systemic Therapy

Nephrectomy Candidate

Prior Systemic Therapy

IRB# 16085 S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

Non-Clear Cell

Papillary Renal Carcinoma

IRB#18121 Nivolumab Combined with Cabozantinib versus Sunitinib

IRB# TBD EAB143: Phase 3 Randomized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER)

No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor

Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4

Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies

IRB#19283 Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic RCC

IRB#17027 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology

IRB#11804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) + Pembro

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment
In Development
Enrollment on Hold

2/5/19